Impending sudden cardiac death: treatment with myocardial revascularization and the automatic implantable cardioverter defibrillator

Major innovations and trends in the medical device sector

Activities related to medical innovation are accelerating and becoming increasingly important due to the demand for better and less invasive therapies, a rapidly aging population in the developed world and a globally larger population able to afford advanced medical care. Medical Innovation is occurring in the fields of pharmacy, diagnostics and therapeutic imaging, surgical products, interventional procedures and devices. Increasing understanding of basic disease processes further opens the opportunities for innovators. Increased knowledge often cause major paradigm shifts in therapeutic methods.

Evaluation of coronary revascularization to prevent tachycardia recurrences in survivors of ventricular fibrillation

Long-term follow-up of 29 consecutive survivors of ventricular fibrillation who underwent revascularization demonstrated that recurrent arrhythmics events were common. Because revascularization alone does not prevent arrhythmia recurrence, treatment with an implantable defibrillator should be considered in these patients.

Operation for ventricular tachyarrhythmias: refining current treatment strategies

For many patients with ventricular tachyarrhythmias, the optimal choice of palliative or curative therapies is not yet well established. To refine optimal current treatment strategies, baseline patient characteristics were studied in relation to likelihood of successful outcome in 240 consecutive patients undergoing operation for treatment of ventricular tachyarrhythmias from 1981 to 1991. Indications for operation were sudden cardiac death or inducible ventricular tachyarrhythmias refractory to medical therapy (or both). Treatment was directed endocardial procedures in 77 patients (32%), other cardiac procedures in 57 patients (24%) (coronary artery bypass grafting in 94% and valve procedure in 14%, either with [35%] or without [65%] concomitant implantable cardioverter-defibrillator), and implantable cardioverter-defibrillator alone in 106 patients (44%). Overall 30-day operative mortality was 5% (70% confidence interval, 4%-7%) and 2-year survival was 74% (70% confidence interval, 71%-77%). Overall 2-year freedom from sudden cardiac death was 97% (70% confidence interval, 96%-98%) and was similar (p = not significant) for all treatment modalities. For each treatment modality, multivariate analysis identified independent risk factors for operative mortality and 2-year tachyarrhythmia recurrence, advanced angina and congestive heart failure New York Heart Association classes, and overall mortality. To characterize better the use and benefit of coronary artery bypass grafting, risk factors related to outcome also were identified for patients stratified according to absence (44 patients) or presence (119 patients) of coronary artery disease excluding patients treated by directed endocardial procedures.(ABSTRACT TRUNCATED AT 250 WORDS)

Simple approach for extrapericardial placement of defibrillator patches via median sternotomy

The intrapericardial placement of implantable cardioverter defibrillator patches has been associated with a variety of complications due to the patch-epicardial interface. Extrapericardial placement of defibrillator patches minimizes these problems. We describe a simple and reproducible technique to achieve this goal whenever a median sternotomy approach is used.

Coronary artery bypass in patients with previously placed implantable defibrillators

Four patients with previously placed implantable defibrillators required coronary revascularization several years after the original device was inserted. Three patients had a conventional system of epicardial patches and leads, and one patient had a nonthoracotomy system placed. All four patients were successfully revascularized without evidence of perioperative infarction or significant morbidity. The patient with the nonthoracotomy device did require manipulation of the endocardial lead at a separate setting. This limited experience suggests that patients needing revascularization after placement of an implantable defibrillator can be successfully bypassed.

Effects of coronary artery bypass grafting on ventricular arrhythmias: results with electrophysiological testing and long-term follow-up

Myocardial revascularization was performed in 56 patients with coronary artery disease who presented with ventricular tachycardia (VT) (n = 39) or ventricular fibrillation (n = 17). There were 46 men and 10 women, aged 65 +/- 10 years. Three vessel (n = 42) or left main disease (n = 4) was present in 82%. Left ventricular ejection fraction averaged 36% +/- 11%. Electrophysiological studies were performed preoperatively in all patients; 50 (89%) had inducible ventricular arrhythmias. Sustained monomorphic VT was induced in 40 patients (cycle length 284 +/- 61 msec). Reproducible symptomatic nonsustained VT was induced in four patients and ventricular fibrillation in six patients, while six patients had no inducible arrhythmia. Preoperatively the patients with inducible VT failed 3.3 +/- 1.2 drug trials during electrophysiological studies. In addition to coronary bypass, 22 patients also received an automatic implantable cardioverter defibrillator (ICD), 26 patients received prophylactic ICD patches, and 1 patient had resection of a false aneurysm. There were no perioperative deaths. Postoperative electrophysiological studies were performed in all 56 surgical survivors. Ventricular tachyarrhythmia could not be induced in the six patients who had no inducible VT preoperatively and in 13 of 40 (33%) with preoperatively inducible sustained VT or in 19 of 50 (38%) patients with any previously inducible ventricular arrhythmia, thus a total of 25 patients (45%) had no inducible VT postoperatively. Of the remaining, 11 patients were treated with antiarrhythmic drugs alone, 11 had already received an ICD (combined with drugs in 7), and another 9 received the ICD postoperatively (combined with drugs in 4).(ABSTRACT TRUNCATED AT 250 WORDS)

Long-term surgical results in sudden death syndrome associated with cardiac dysfunction after myocardial infarction

To evaluate the surgical results in patients with inducible ventricular tachyarrhythmias due to coronary disease and left ventricular dysfunction, the authors reviewed their experience in 170 patients who had survived one or more cardiac arrests after myocardial infarction and were unresponsive to drug therapy based on electrophysiologic studies (EPS). There were nine operative deaths (5%). Based on intraoperative EPS, surgical remodeling of left ventricular dysfunction (aneurysm resection, infarct debulking, and septal reinforcement) with map-guided cryoablation and coronary artery bypass graft was performed in 34 patients (group A), and left ventricular remodeling and coronary artery bypass graft without guided endocardial resection was performed in 25 patients (group B). Forty-three patients (group C) had coronary artery bypass graft with implantation of an automatic implantable cardioverter defibrillator (AICD). Group D (68 patients) received AICD only. After operation, based on EPS results, four patients in group A (12%) and three patients in Group B (15%) required AICD implantation. Overall survival at 6 years was 65%, 48%, 85%, and 58% in patient groups A, B, C, and D, respectively (p = not significant). During follow-up in group A patients, none died suddenly and none needed AICD. In group B, two patients required AICD 3 and 5 years later, and five patients died suddenly. The incidence of sudden death was 2.3%/patient/year and 3.5%/patient/year after AICD implantation (groups C and D). At 6 years, cardiac-event-free survival was 80% and 70% for groups A and B and 38% and 24% for groups C and D, respectively (p less than 0.001). Patients receiving map-guided ablative procedures had significantly improved cardiac-event-free survival rates.

Prevention of sudden death in survivors of myocardial infarction: a decision analysis approach

During the first year after myocardial infarction, 5% to 15% of patients die, and the majority of deaths occur suddenly. Highly efficacious therapy, such as the implantable cardioverter-defibrillator, may reduce the chance of sudden death, but broad application is limited by associated risks. Hence, attempts to identify patients at high risk so they can receive therapy are desirable. Subgroups with high or low sudden death risks can be identified based on left ventricular function. Further risk stratification using programmed electrical stimulation and the signal-averaged ECG has been advocated, but the best strategy is unknown. Using a decision analysis model, we compared the 1-year survival rates in survivors of myocardial infarction treated with the implantable cardioverter-defibrillator either empirically or based on screening with the signal-averaged ECG and programmed electrical stimulation. The best strategy for selecting patients for therapy depended on the pre-therapy sudden death risk. For patients at low risk, such as those with well-preserved ventricular function, antiarrhythmic therapy selected with screening tests or given empirically increased both the mortality rate resulting from the adverse effects of therapy and the excellent survival rate without therapy. In the moderate-risk population, both empiric and stratified approaches reduced mortality, but stratification substantially limited the number of patients receiving unnecessary therapy. In the high-risk population, empiric treatment achieved the best survival rate, and screening resulted in only a small reduction in the number of patients treated unnecessarily.(ABSTRACT TRUNCATED AT 250 WORDS)

Retrospective analysis of patients undergoing one- or two-stage strategies for myocardial revascularization and implantable cardioverter defibrillator implantation

Internal defibrillation leads were placed at time of coronary revascularization in 79 patients. In 34, an implantable cardioverter defibrillator (ICD) was placed simultaneously (group I). A two-stage strategy (selective implantation of the ICD in patients with postoperative spontaneous or inducible ventricular tachycardia [VT]) was followed in 45 patients (group II). Group I patients had failed more antiarrhythmic drug trials (2.9 +/- 1.6 vs 1.5 +/- 1.6; P = 0.02), including amiodarone (62% vs 20%; P less than 0.001). There were four operative deaths in each group. Postoperatively, VT was present in 27 group II patients (60%), 25 of whom received an ICD (two refused device implantation). Patients with postoperative VT had a lower left ventricular ejection fraction than those without VT (33 +/- 9 vs 47 +/- 16; P = 0.01). Actuarial survival at 1, 2, and 3 years was 88 +/- 6, 88 +/- 7, and 88 +/- 10 in group I; and 83 +/- 6, 76 +/- 7, and 76 +/- 11 in group II (NS). No patient without an ICD (based on the postoperative electrophysiological study [EPS]) died suddenly. Five patients (6%) had ICD system infection. Sudden death was largely prevented by either strategy, but relatively high rates of operative mortality and ICD system infection were observed. Prospective studies should identify patients more likely to benefit from one or another strategy.

The role of the automatic implantable cardioverter-defibrillator (AICD) in the treatment of medically refractory ventricular arrhythmias

After 6 years of widespread clinical use, the role of the automatic implantable cardioverter-defibrillator (AICD) is well defined in some circumstances and less well defined in others. In the next year, the second generation of this device will become available, incorporating antitachycardia pacing algorithms and programmable delivered-energy capabilities into the basic defibrillator system. As a prelude to this development, this article addresses the current status and future role of the AICD in the overall therapeutic armamentarium for the treatment of ventricular tachycardia and presentation of sudden death.

Automatic implantable cardioverter-defibrillator implantation without thoracotomy using an endocardial and submuscular patch system

The automatic cardioverter-defibrillator lead system is implanted by a thoracotomy procedure that may result in atelectasis, pleural effusion, cardiac tamponade and lengthy convalescence. A new defibrillator lead system that allows selection of different defibrillating current pathways is implanted without a thoracotomy. Ten patients requiring a cardioverter-defibrillator for recurrent sustained ventricular tachycardia (five patients) or aborted sudden cardiac death (five patients) were evaluated for implantation of this lead system. A lead configuration with a bidirectional defibrillating current pathway was implanted in nine patients. The defibrillation threshold with this lead configuration was 15 J in five patients, 20 J in three and 30 to 35 J in one patient. In the remaining patient the lead system had a 40 J defibrillation threshold and was not implanted. No perioperative complications occurred. Induced ventricular fibrillation was successfully terminated at the predischarge and intermediate follow-up (8 to 12 weeks) electrophysiologic studies. During the follow-up period, there were three deaths (one sudden, two due to heart failure) and two lead system failures (oversensing with inappropriate shocks in one patient and patch lead fracture in another). Implantation of the cardioverter-defibrillator lead system by a nonthoracotomy approach is feasible, has no significant perioperative complications and is well tolerated by patients. Effective defibrillation was demonstrated immediately as well as at intermediate follow-up study. The occurrence of patch lead fracture and oversensing requires improvement in the present (nonthoracotomy) lead system technology.

Safety of external cardioversion/defibrillation in patients with internal defibrillation patches and no device

Placement of prophylactic epicardial defibrillation patches at time of open-heart surgery in patients at risk for postoperative arrhythmias has been strongly questioned. Concern has centered on the ability to safely perform subsequent external defibrillation if needed. From 61 patients who were treated with a two-stage strategy we identified 17 who, while wearing epicardial patches and no generator, received external cardioversion/defibrillation for 20 episodes of hemodynamically unstable ventricular arrhythmias. All the patients had one small and one large patch. Eighteen of the episodes were induced during electrophysiological testing (with transthoracic shocks delivered via pad electrodes oriented in an apex-posterior configuration) and two were spontaneous. The episodes occurred at 21 +/- 27 days from patch implant. Thirteen episodes (65%) were converted with one shock at an energy level of 185 +/- 65 J. Seven (35%) required a second shock at 351 +/- 22 J. The accumulated energy requirement was 286 +/- 205 J. No adverse outcomes were noted. The number of episodes requiring more than one shock and the energy requirements were not different from those in a control group of 20 similar arrhythmias treated with the same equipment. Under these conditions, external cardioversion/defibrillation in patients with one large and one small epicardial defibrillation patch was uniformly successful. Further data is needed in the out-of-hospital setting and on the results of external defibrillation in patients with two large patches.

Evolving patterns in the surgical treatment of malignant ventricular tachyarrhythmias

The advent of the automatic implantable cardioverter defibrillator (AICD), generally viewed as a safe and effective intervention, has in some measure discouraged the use of electrophysiologically directed endocardial resection for intractable ventricular arrhythmias. We reviewed the records of 127 patients undergoing either AICD procedures or resection over a 6-year period. Thirty-day mortality was 5.6% (5/89 patients) for all AICD procedures, 10.7% (3/28) for AICD placement plus coronary artery bypass grafting, and 11.8% (4/34) for resection. These mortality figures are not significantly different. Patients undergoing resection were less likely to require antiarrhythmic agents than patients given an AICD (33% versus 61%). Survival at 2 years was 78% in the resection group and 72% in the AICD group. Survival at 4 years was still 78% in the resection group. Only 1 late sudden death occurred in the AICD group and none in the resection group. We conclude that resection continues to be a valuable alternative, offering a greater overall benefit at only slightly increased risk.

Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator

Seventy-seven patients with drug-refractory sustained ventricular tachycardia (VT) (28 patients) or ventricular fibrillation (VF) (49 patients) underwent implantation of an automatic cardioverter defibrillator (AICD). The 67 men and 10 women, with a mean age of 60 +/- 12 years (range 18 to 79), had coronary artery disease (60 patients), idiopathic cardiomyopathy (eight patients), mitral valve prolapse (four patients), hypertensive heart disease (one patient), Ebstein's anomaly (one patient), long QT syndrome (one patient), and primary electrical disease (two patients). The mean left ventricular ejection fraction was 35 +/- 16% (range 10% to 75%). Sustained VT/VF was induced in 64 patients (83%) at baseline electrophysiologic testing. A mean of 4.1 +/- 1.3 antiarrhythmic drugs failed to control the arrhythmia. Associated surgery at AICD implantation included coronary artery bypass in 19 patients, coronary bypass with aneurysmectomy in six patients, and aneurysmectomy alone in one patient. Five patients had only prophylactic patches implanted during aneurysmectomy or coronary bypass and the AICD device was subsequently implanted under local anesthesia to prevent arrhythmia recurrence or to control persistently inducible VT. Operative mortality was 2.6% with two deaths from intractable VF. Fifty-two patients (69%) continued receiving antiarrhythmic drugs to suppress spontaneous VT. During a mean follow-up of 15 +/- 13 months (range 1 to 63), six patients died: two suddenly due to probable pulse generator failure (greater than 2 years old), one of acute myocardial infarction, two of heart failure, and one of respiratory failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Early experience with the automatic implantable cardioverter defibrillator in sudden death survivors

Medical management of life-threatening ventricular arrhythmias is difficult because of the toxicity and limited efficacy of antiarrhythmic drugs. The automatic implantable cardioverter defibrillator (AICD) offers protection against malignant ventricular arrhythmias and allows some patients to be managed without antiarrhythmic drugs. We reviewed our experience with the AICD to determine its safety and efficacy. Since June 1987, 24 patients (mean age 63 years) who survived out-of-hospital ventricular fibrillation or hemodynamically unstable ventricular tachycardia not associated with acute myocardial infarction had implantation of an AICD. None had inducible monomorphic ventricular tachycardia associated with ventricular aneurysm. Twenty-three had abnormal left ventricular function (mean ejection fraction 0.32). There were no operative deaths and three complications. At last follow-up (mean 8.9 months) 23 patients were alive. Eight patients had one or more AICD discharges associated with symptomatic or monitored cardiac arrest. AICD implantation can be performed with low risk and appears to be an effective alternative to antiarrhythmic therapy with toxic drugs.

Prophylactic automatic implantable cardioverter-defibrillator patches in patients at high risk for postoperative ventricular tachyarrhythmias

The strategy of placing prophylactic patches for the automatic implantable cardioverter-defibrillator (AICD) without the AICD was employed in 34 patients with coronary artery disease at risk for postoperative ventricular tachycardia undergoing coronary bypass graft surgery (12 patients) or subendocardial resection (22 patients). Patients were selected on the basis of the presence of preoperative sustained ventricular tachycardia (25 patients) or ventricular fibrillation (9 patients) and absence of control of the arrhythmia with 3.6 +/- 1.3 antiarrhythmic drugs by programmed stimulation. Patients having subendocardial resection were also selected on the basis of multiple configurations of ventricular tachycardia, inability to map the tachycardia or posterior wall aneurysm. The surgical mortality rate was 12%, with two deaths after coronary bypass graft surgery and two deaths after subendocardial resection. The AICD patches were removed in 1 of the 34 patients a few hours after surgery because of left atrial laceration and bleeding. Among 10 patients surviving coronary bypass surgery alone, ventricular arrhythmia was not inducible in 6 and in 4 it remained inducible postoperatively. One of the four patients with inducible arrhythmia had the AICD implanted with use of local anesthesia; the other three were treated with drugs. Among 20 patients surviving subendocardial resection, ventricular arrhythmia was noninducible in 15 and remained inducible in 5. Three of these five patients had an AICD implanted; the other two were treated with drugs. At 12 +/- 7 month follow-up, there were no late deaths.(ABSTRACT TRUNCATED AT 250 WORDS)